Evolving Management of FSGS: Proteinuria and Clinical Data
Ft. Drs. Daniel Gale and Gaia Coppock
Dr. Chee Kay Cheung, MBChB, MRCP, PhD, FHEA, is a Consultant Nephrologist and Honorary Associate Professor at the University Hospitals of Leicester NHS Trust, UK, with expertise in glomerular diseases, IgA nephropathy, vasculitis, and lupus nephritis
In this episode of the Rare Kidney Disease Show, host Chris Gisler is joined by Dr. Chee Kay Cheung of the University of Leicester to discuss how proteinuria targets in IgA nephropathy (IgAN) are changing. They ask whether achieving very low levels of proteinuria can tell us something meaningful about the future trajectory of kidney function.
They cover why treatment targets have changed, what exactly has changed, and why the definition of a good treatment response has become more ambitious.
The discussion draws on 2 data sources:
Using these data, the speakers dive deeper into how proteinuria relates to prognosis. They also consider the potential for complete remission and slowing eGFR decline.
Also find us on: Apple Podcasts Spotify Vimeo
“Previous targets really reflected the available evidence at the time. But much of this was derived from relatively small studies, maybe a few hundred patients, from small numbers of centers. And patients were followed for a relatively brief period of time, maybe 5 to 10 years. More recent registry data has included far larger numbers of patients, followed for a much longer period of time. And now we’re really thinking about the lifetime risk that people have of developing kidney function decline or kidney failure.”
“More recent observational data, and this is data from the RADAR study, but also US data from the Kaiser Permanente database, from China, from Sweden, emphasizes, really, that the lower we can drive proteinuria, the better the outcomes.”
“With both sparsartan and irbesartan, when you exclude the first 6 weeks and look at the GFR slope for the remainder of the study, the eGFR decline was -0.7 mL/min/year in the complete remission group, versus -4.2 mL/min/year in the non-remission group. So, that between-group difference in the chronic eGFR slope was very statistically significant.”
The lower the proteinuria the better; there is no “safe” threshold. IgA nephropathy risk does not disappear below 1 g/day. Even modest residual proteinuria is associated with meaningful lifetime kidney-failure risk, supporting more ambitious targets of <0.5 g/day and ideally <0.3 g/day.
Complete proteinuria remission is associated with substantially better kidney outcomes. In the post hoc PROTECT analysis, patients achieving proteinuria <0.3 g/day had slower annual eGFR decline (−0.7 vs. −4.2 mL/min/year) and fewer composite kidney events (1% vs. 14%) than those who did not achieve remission.
Proteinuria and eGFR should be treated as complementary measures. Preserving eGFR and preventing kidney failure remain the ultimate goals, while proteinuria provides an earlier, actionable indicator of disease activity and residual risk. The clinical implication is to diagnose earlier, treat more aggressively, and escalate therapy when proteinuria remains above target.
DISCLAIMER: Guest speakers of the Rare Kidney Disease Show may be paid consultants of Travere Therapeutics. This podcast episode was recorded on September 29, 2026. Please always consult updated sources for the latest information, as information discussed may have changed since the recording date.
MA-IgAN-26-0003
More Episodes Like This
Evolving Management of FSGS: Proteinuria and Clinical Data
Ft. Drs. Daniel Gale and Gaia Coppock
Endothelin & Proteinuria in Glomerular Pathophysiology
Ft. Dr. Donald Kohan and Dr. Yelena Drexler
Insights from the SPARTAN Study
Ft. Drs. Jonathan Barratt and Shikha Wadhwani
MA-IgAN-26-0004 | November 2026